投稿系统
-
Abstract: Bladder cancer (BC) ranks as the tenth most common cancer globally. Histopathologically, BC is broadly categorized into urothelial and non-urothelial BC. Urothelial carcinoma represents over 90% of BC in most regions worldwide. The standard treatment procedure for diagnosing and treating non-muscle-invasive bladder cancer (NMIBC) is transurethral resection of bladder tumors (TURBT). Currently, the standard of care for muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy followed by radical cystectomy. Cryoablation therapy is a medical technique that uses extremely low temperatures to destroy diseased tissue. This treatment serves as a therapeutic tool for both benign and malignant diseases in organs such as the kidney, prostate gland, lung, liver, and breast, and is particularly effective for unresectable tumors, offering less trauma, quick recovery, good tolerability, and symptom control. However, cryoablation has its limitations. Over the past few years, cryoablation therapy has emerged as a new method for treating early BC. This treatment is minimally invasive, precise, and offers quick recovery, providing patients with a new treatment option. Although randomized studies are still limited, increasing evidence suggests its potential application in bladder cancer combined with transurethral resection (TURBT) or medication. Cryoablation is not standard therapy for bladder cancer. Treatment decisions should be discussed by a multidisciplinary team of urologists, oncologists, and interventional physicians and require more randomized controlled trials to define patient selection criteria and treatment approaches.
-
[1] Burger M, Catto J W, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 2013; 63: 234-241. doi: 10.1016/j.eururo.2012.07.033 [2] Georgantzoglou N, Pergaris A, Masaoutis C, et al. Extracellular vesicles as biomarkers carriers in bladder cancer: diagnosis, surveillance, and treatment. Int J Mol Sci, 2021; 22(5): 2744. doi: 10.3390/ijms22052744 [3] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012: Global Cancer Statistics, 2012. CA Cancer J. Clin, 2015; 65: 87-108. doi: 10.3322/caac.21262 [4] Dahm P, Gschwend J E. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur. Urol, 2003; 44: 672-681. doi: 10.1016/S0302-2838(03)00416-0 [5] Comperat E, Larre S, Roupret M, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch, 2015; 466: 589-594. doi: 10.1007/s00428-015-1739-2 [6] IARC, Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. Accessed on March 2022. https://gco.iarc.fr/today/online-analysis-table .[7] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018; 68: 394-424. doi: 10.3322/caac.21492 [8] Logan C, Brown M, Hayne D. Intravesical therapies for bladder cancer - indications and limitations. BJU Int, 2012; 110 Suppl 4: 12-21. doi: 10.1111/j.1464-410X.2012.11619.x [9] Flaig T W, Spiess P E, Agarwal N, et al. NCCN guidelines insights: bladder cancer, version 5.2018. J Natl Compr Canc Netw, 2018; 16: 1041-1053. doi: 10.6004/jnccn.2018.0072 [10] Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol, 2002; 41: 523-531. doi: 10.1016/S0302-2838(02)00068-4 [11] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019. CA Cancer J Clin, 2019; 69(1): 7-34. doi: 10.3322/caac.21551 [12] Charlton M E, Adamo M P, Sun L, et al. Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010. Cancer, 2014; 120(Suppl 23): 3815-3825. doi: 10.1002/cncr.29047 [13] Chang S S, Bochner B H, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol, 2017; 198(3): 552-559. doi: 10.1016/j.juro.2017.04.086 [14] Sternberg C N, Skoneczna I, Kerst J M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol, 2015; 16: 76-86. doi: 10.1016/S1470-2045(14)71160-X [15] Stenzl A, Cowan N C, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol, 2009; 55: 815-825. doi: 10.1016/j.eururo.2009.01.002 [16] Vrooman O P, Witjes J A. Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol, 2010; 20: 437-442. doi: 10.1097/MOU.0b013e32833cf10e [17] Cagiannos I, Morash C. Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J, 2009; 3: S237-242 doi: 10.5489/cuaj.1205 [18] M J Mathers J Z, S Wyler, S Roth, et al. Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers. World J Urol, 2008; 26: 251-256. doi: 10.1007/s00345-008-0244-5 [19] Bekku K, Saika T, Kobayashi Y, et al. Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? Int J Clin Oncol, 2013; 18: 110-115. doi: 10.1007/s10147-011-0350-z [20] Lehmann J, Suttmann H, Albers P, et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol, 2009; 55: 1293-1299. doi: 10.1016/j.eururo.2008.11.039 [21] Ghandour R, Singla N, Lotan Y. Treatment options and outcomes in nonmetastatic muscle invasive bladder cancer. Trends Cancer, 2019; 5(7): 426-439. doi: 10.1016/j.trecan.2019.05.011 [22] Alfred Witjes J, Lebret T, Compérat E M, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol, 2017; 71(3): 462-475. doi: 10.1016/j.eururo.2016.06.020 [23] Flaig T W, Spiess P E, Agarwal N, et al. NCCN guidelines insights: bladder cancer, version 5.2018. J Natl Compr Canc Netw, 2018; 16(9): 1041-1053. doi: 10.6004/jnccn.2018.0072 [24] Ploussard G, Daneshmand S, Efstathiou J A, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol, 2014; 66(1): 120-137. doi: 10.1016/j.eururo.2014.02.038 [25] Dunst J, Sauer R, Schrott K M, et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys, 1994; 30(2): 261-266. doi: 10.1016/0360-3016(94)90003-5 [26] Shipley W U, Prout G R Jr, Einstein A B, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA, 1987; 258(7): 931-935. doi: 10.1001/jama.258.7.931 [27] Hussain S A, Stocken D D, Peake D R, et al. Long-term results of a phase Ⅱ study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer, 2004; 90(11): 2106-2111. doi: 10.1038/sj.bjc.6601852 [28] Choudhury A, Swindell R, Logue J P, et al. Phase Ⅱ study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol, 2011; 29(6): 733-738. doi: 10.1200/JCO.2010.31.5721 [29] Hoskin P J, Rojas A M, Bentzen S M, et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol, 2010; 28(33): 4912-4918. doi: 10.1200/JCO.2010.28.4950 [30] Fransen van de Putte E E, Pos F, Doodeman B, et al. Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer. J Urol, 2019; 201(3): 478-485. doi: 10.1016/j.juro.2018.10.007 [31] Gakis G, Efstathiou J, Lerner S P, et al. ICUD-EAU International consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol, 2013; 63(1): 45-57. doi: 10.1016/j.eururo.2012.08.009 [32] Amoils S P. The Joule Thomson cryoprobe. Arch Ophthalmol, 1967; 78: 201-207. doi: 10.1001/archopht.1967.00980030203014 [33] Coldwell D M, Sewell P E. The expanding role of interventional radiology in the supportive care of the oncology patient: from diagnosis to therapy. Semin Oncol, 2005; 32: 169-173. doi: 10.1053/j.seminoncol.2004.11.018 [34] Mu F, Niu L, Li H, et al. Percutaneous comprehensive cryoablation for metastatic hepatocellular cancer. Cryobiology, 2013; 66: 76-80. doi: 10.1016/j.cryobiol.2012.11.008 [35] Niu L Z, Li J L, Zeng J Y, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol, 2013; 19: 3473-3480. doi: 10.3748/wjg.v19.i22.3473 [36] Niu L, Mu F, Zhang C, et al. Cryotherapy protocols for metastatic breast cancer after failure of radical surgery. Cryobiology, 2013; 67: 17-22. doi: 10.1016/j.cryobiol.2013.04.004 [37] Kwak K, Yu B, Lewandowski R J, et al. Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation. Theranostics, 2022; 12(5): 2175-2204. doi: 10.7150/thno.67530 [38] Solomon S B, Silverman S G. Imaging in interventional oncology. Radiology, 2010; 257: 624-640. doi: 10.1148/radiol.10081490 [39] Link R E, Permpongkosol S, Gupta A, et al. Cost analysis of open, laparoscopic, and percutaneous treatment options for nephron-sparing surgery. J Endourol, 2006; 20: 782-789. doi: 10.1089/end.2006.20.782 [40] Aarts B M, Klompenhouwer E G, Rice S L, et al. Cryoablation and immunotherapy: an overview of evidence on its synergy. Insights Imaging, 2019; 10: 53. doi: 10.1186/s13244-019-0727-5 [41] Ito N, Nakatsuka S, Inoue M, et al. Computed tomographic appearance of lung tumors treated with percutaneous cryoablation. J Vasc Interv Radiol, 2012; 23: 1043-1052. doi: 10.1016/j.jvir.2012.04.033 [42] Saliken J C, McKinnon J G, Gray R. CT for monitoring cryotherapy. AJR Am J Roentgenol, 1996; 166: 853-855. doi: 10.2214/ajr.166.4.8610562 [43] Niu L, Xu K, Mu F. Cryosurgery for lung cancer. J Thorac Dis, 2012; 4: 408-419. doi: 10.1142/9789814329668_0021 [44] Hinshaw J L, Durick N, Leung W, et al. Radiology-pathology correlation of pulmonary cryoablation in a porcine model. J Intervent Oncol, 2009; 2: 113-120. [45] Hinshaw J L, Littrup P J, Durick N, et al. Optimizing the protocol for pulmonary cryoablation: a comparison of a dual- and triple-freeze protocol. Cardiovasc Intervent Radiol, 2010; 33(6): 1180-1185. doi: 10.1007/s00270-010-9868-0 [46] Maj R, Iacopino S, Stroker E, et al. Mid-term outcome following second-generation cryoballoon ablation for atrial fibrillation in heart failure patients: effectiveness of single 3-min freeze cryoablation performed in a cohort of patients with reduced left ventricular systolic function. J Cardiovasc Med (Hagerstown), 2019; 20: 667-675. doi: 10.2459/JCM.0000000000000845 [47] Cha C, Lee F T Jr, Rikkers L F, et al. Rationale for the combination of cryoablation with surgical resection of hepatic tumors. J Gastrointest Surg, 2001; 5: 206-213. doi: 10.1016/S1091-255X(01)80034-2 [48] Glazer D I, Tatli S, Shyn P B, et al. Percutaneous image-guided cryoablation of hepatic tumors: single-center experience with intermediate to long-term outcomes. AJR Am J Roentgenol, 2017; 209: 1381-1389. doi: 10.2214/AJR.16.17582 [49] Deng W, Chen L, Wang Y, et al. Cryoablation versus partial nephrectomy for clinical stage T1 renal masses: a systematic review and meta-analysis. J Cancer, 2019; 10: 1226-1236. doi: 10.7150/jca.28881 [50] Pecoraro A, Palumbo C, Knipper S, et al. Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer. J Urol, 2019; 202: 1120-1126. doi: 10.1097/JU.0000000000000460 [51] Sohn R L, Carlin A M, Steffes C, et al. The extent of cryosurgery increases the complication rate after hepatic cryoablation. Am Surg, 2003; 69: 317-322. doi: 10.1177/000313480306900408 [52] Bouhamama A, Wdowik Q, Grillet F, et al. Prognostic factors for local recurrence after cryoablation of desmoid tumors. J Vasc Interv Radiol, 2023; 34(9): 1538-1546. doi: 10.1016/j.jvir.2023.05.012 [53] McDonald D F, Mobley T L, Rudolph J H. Cryotherapy of a heterografted human bladder tumor. Long-term observations. Cryobiology, 1966; 2(5): 280-284. doi: 10.1016/S0011-2240(66)80136-0 [54] McDonald D F, Mobley T L, Rudolph J H. Cryotherapy of a heterografted human bladder tumor. J Urol, 1966; 95(4): 526-530. doi: 10.1016/S0022-5347(17)63491-8 [55] Cahan W G, Adam Y, Mackenzie R A, et al. Intractable bladder hemorrhage treated by cryosurgery: a preliminary report. J Urol, 1970; 103(5): 606-611. doi: 10.1016/S0022-5347(17)62011-1 [56] Mackenzie A R. Cryotherapy of the bladder for cancer. J Urol, 1972; 107(3): 387-388. doi: 10.1016/S0022-5347(17)61035-8 [57] McDonald J, Taylor C B, Heckel N J. Rapid freezing of the bladder: an experimental and clinical study. J Urol, 1950; 64: 326-337. doi: 10.1016/S0022-5347(17)68637-3 [58] Permpongkosol S, Nicol T L, Kavoussi L R, et al. Percutaneous bladder cryoablation in porcine model. J Endourol, 2006; 20: 991-995. doi: 10.1089/end.2006.20.991 [59] Mou Z, Chen Y, Zhang Z, et al. Cryoablation inhibits the recurrence and progression of bladder cancer by enhancing tumour-specific immunity. Clin Transl Med, 2023; 13: 1255. doi: 10.1002/ctm2.1255 [60] Littrup P J, Mody A, Sparschu R, et al. Prostatic cryotherapy: ultrasonographic and pathologic correlation in the canine model. Urology, 1994; 44: 175-183. doi: 10.1016/S0090-4295(94)80123-1 [61] Li J, Chen J, Zhou L, et al. Comparison of dual- and triple-freeze protocols for hepatic cryoablation in a Tibet pig model. Cryobiology, 2012; 65: 68-71. doi: 10.1016/j.cryobiol.2012.04.004 [62] Marjara J, Hilli J, Davis R M, et al. Metastatic retro-crural lymph nodes from transitional cell carcinoma of bladder successfully treated with single session cryoablation. Radiol Case Rep, 2020; 15: 1197-1201. doi: 10.1016/j.radcr.2020.05.022 [63] Zhang Q, Zhang S, Zhang S, et al. Transperineal cryotherapy for unresectable muscle invasive bladder cancer: preliminary experience with 7 male patients. BMC Urol, 2017; 17: 81. doi: 10.1186/s12894-017-0270-y [64] Sun L, Zhang W, Liu H, et al. Computed tomography imaging-guided percutaneous argon-helium cryoablation of muscle-invasive bladder cancer: initial experience in 32 patients. Cryobiology, 2014; 69: 318-322. doi: 10.1016/j.cryobiol.2014.08.006 [65] Liang Z, Fei Y, Lizhi N, et al. Percutaneous cryotherapy for metastatic bladder cancer: experience with 23 patients. Cryobiology, 2014; 68: 79-83. doi: 10.1016/j.cryobiol.2013.12.004 [66] Xu C, Jiang S, Zou L, et al. Endoscopic balloon cryoablation plus transurethral resection for bladder cancer: A phase 2, multicenter, randomized, controlled trial. Cancer, 2023; 129: 415-425. doi: 10.1002/cncr.34563 [67] Gage A A, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology, 1998; 37: 171-186. doi: 10.1006/cryo.1998.2115 [68] Yakkala C, Denys A, Kandalaft L, et al. Cryoablation and immunotherapy of cancer. Curr Opin Biotechnol, 2020; 65: 60-64. doi: 10.1016/j.copbio.2020.01.006 [69] Srivastava P K. Hypothesis: controlled necrosis as a tool for immunotherapy of human cancer. Cancer Immun, 2003; 18: 4. [70] Liu S, Zou L, Mao S, et al. The safety and efficacy of bladder cryoablation in a beagle model by using a novel balloon cryoprobe. Cryobiology, 2016; 72: 157-160. doi: 10.1016/j.cryobiol.2016.02.007 [71] Liu S, Zhang L, Zou L, et al. The feasibility and safety of cryoablation as an adjuvant therapy with transurethral resection of bladder tumor: a pilot study. Cryobiology, 2016; 73(2): 257-260. doi: 10.1016/j.cryobiol.2016.07.001 -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 153
- HTML全文浏览量: 90
- PDF下载量: 8
- 被引次数: 0
